Arcellx (ACLX) Cash & Equivalents (2021 - 2025)
Arcellx (ACLX) recorded quarterly Cash & Equivalents of $80.3 million in Q4 2025, up 1.59% quarter-over-quarter from $79.0 million in Q3 2025, and down 24.05% on a YoY basis from $105.7 million in Q4 2024.
Arcellx (ACLX) Cash & Equivalents (2021 - 2025) Analysis & Trends
Arcellx's Cash & Equivalents history runs 5 years deep, the most recent figure standing at $80.3 million for Q4 2025.
- In Q4 2025, Cash & Equivalents fell 24.05% year-over-year to $80.3 million; the TTM figure through Dec 2025 stood at $80.3 million (down 24.05% YoY), while the FY2025 annual figure was $80.3 million, down 24.05% from the prior year.
- Cash & Equivalents was $80.3 million for Q4 2025 at Arcellx, up from $79.0 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $394.6 million in Q4 2023 to a low of $30.8 million in Q4 2021.
- Historically, Cash & Equivalents has averaged $134.9 million across 5 years, with a median of $111.7 million in 2021.
- The sharpest annual moves came in 2023 and 2024: Cash & Equivalents jumped 514.82% in 2023, then plunged 73.22% in 2024.
- A 5-year view of Cash & Equivalents shows it stood at $30.8 million in 2021, then jumped by 108.15% to $64.2 million in 2022, then surged by 514.82% to $394.6 million in 2023, then slumped by 73.22% to $105.7 million in 2024, then retreated by 24.05% to $80.3 million in 2025.
- The last three Cash & Equivalents figures came in at $80.3 million (Q4 2025), $79.0 million (Q3 2025), and $62.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 1.91 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 7.15 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.49 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 558.94 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 80.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 80.26 Mn |
| Sep 30, 2025 | 79.01 Mn |
| Jun 30, 2025 | 62.34 Mn |
| Mar 31, 2025 | 80.86 Mn |
| Dec 31, 2024 | 105.68 Mn |
| Sep 30, 2024 | 161.85 Mn |
| Jun 30, 2024 | 100.03 Mn |
| Mar 31, 2024 | 154.57 Mn |
| Dec 31, 2023 | 394.58 Mn |
| Sep 30, 2023 | 126.12 Mn |
| Jun 30, 2023 | 303.67 Mn |
| Mar 31, 2023 | 274.89 Mn |
| Dec 31, 2022 | 64.18 Mn |
| Sep 30, 2022 | 56.76 Mn |
| Jun 30, 2022 | 164.54 Mn |
| Mar 31, 2022 | 127.16 Mn |
| Dec 31, 2021 | 30.83 Mn |
| Sep 30, 2021 | 70.03 Mn |
| Jun 30, 2021 | 143.79 Mn |
| Mar 31, 2021 | 117.65 Mn |